Needle Comparison for Diagnosing Sarcoidosis
Trial Summary
What is the purpose of this trial?
This randomized pilot clinical trial aims to examine whether sample collection with Franseen-type needles are effective for the diagnosis of sarcoidosis, as defined by improved sample quality for pathological diagnosis compared to the conventional Menghini-type needle.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment EBUS-TBNA for diagnosing sarcoidosis?
Is EBUS-TBNA safe for diagnosing sarcoidosis?
How does the treatment EBUS-TBNA differ from other treatments for sarcoidosis?
Research Team
Kazuhiro Yasufuku
Principal Investigator
UHN
Eligibility Criteria
This trial is for individuals with sarcoidosis, a condition where tiny clumps of inflammatory cells grow in different parts of the body. Participants should be suitable candidates for a procedure called EBUS-TBNA, which collects tissue samples from the lungs.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo EBUS-guided transbronchial needle aspiration using either Menghini-type or Franseen-type needles
Post-procedural assessment
Post-procedural assessment in the endoscopy recovery room, including monitoring of vital signs, signs of bleeding, and pulmonary status
Follow-up
Participants are monitored for safety and effectiveness after the procedure
Treatment Details
Interventions
- EBUS-TBNA
EBUS-TBNA is already approved in European Union, United States, Japan for the following indications:
- Mediastinal and hilar lymph node staging for non-small cell lung cancer
- Mediastinal and hilar lymph node staging for non-small cell lung cancer
- Mediastinal and hilar lymph node staging for non-small cell lung cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor